Undeterred by the failure of its lead non-alcoholic steatohepatitis (NASH) drug, selonsertib, in a key Phase III trial as announced in February 2019, Gilead has agreed to a three-year collaboration with insitro to develop NASH therapies for up to five targets. The deal will utilise insitro’s human technology, which combines large data sets and machine learning, to create disease models and discover targets for the partnership. Aside from selonsertib, Gilead has Phase II assets cilofexor and firsocostat in its NASH arsenal.